Revox™ Line Relaxer
Now available in larger sizes
Welcome!
Thank you so much for stopping by to learn more about Revox™ Line Relaxer!
Click the tabs above to learn more about our newest breakthrough innovation.
Revox™ Line Relaxer Product Information & Procedure Pairing Clinical Findings
Learn more about Revox™ Line Relaxer and our clinical study where we paired the product with neuromodulator, from our Director of Research and Clinical Development, Alisar Zahr, PhD.
Launch the Procedure Pairing Clinical Study PodcastRevox™ Line Relaxer General Product Information
Learn more about Revox™ Line Relaxer and hear frequently asked questions, answered from our Education Team.
Launch the Product Information PodcastConfidential and Proprietary: These webpages contains technical information intended for educational purposes only, and may not be modified, duplicated or distributed in any manner.
What is Revox™ Line Relaxer?
- Revox™ Line Relaxer is an advanced targeted serum that helps to significantly impact the appearance of horizontal and vertical expression lines.
- The 8-peptide formula utilizes patent-pending LineRelax™ technology to work in synergy with a neuromodulator to deliver the best of both worlds for dramatic, natural-looking results.
- The breakthrough formula also is clinically proven to significantly improves radiance, texture, and overall appearance.
Key Product Claims
- After 12 weeks, there was 100% greater improvement in under-eye fine lines and wrinkles at rest when a neuromodulator was paired with Revox™ Line Relaxer vs. vehicle control*(1)
- After using Revox™ Line Relaxer alone, subjects showed a 29% average reduction in expression lines and under-eye lines after 8 weeks, and a 38% average reduction after 12 weeks (2)
- Advanced patent-pending LineRelax™ Technology featuring 5 neuromodulating bioavailable peptides plus Gamma-Aminobutyric Acid (GABA) not only reduces the intensity of expression lines by inhibiting acetylcholine release from the nerve ending to the muscle, but also works at the epidermal level mitigating the release of acetylcholine from the keratinocyte and dissemination throughout the facial skin
* Vehicle Control represents neuromodulator plus placebo serum
(1) Based on a Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Split-Face Study Evaluating Procedure pairing a Peptide Anti-Aging Serum with OnabotulinumtoxinA in the treatment of Periorbital Facial Wrinkles. Results may vary.
(2) Nguyen, TQ; Zahr, AZ; Kononov, T; Ablon, G. A Randomized, Double-Blind, Placebo-Controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum Targeting Expression Lines. Journal of Clinical and Aesthetic Dermatology. May 2021. Accepted. Results may vary.
Patent-Pending LineRelax™ Technology
Breakthrough, patent-pending LineRelax™ Technology features 5 neuromodulating bioavailable peptides plus Gamma-Aminobutyric Acid (GABA)
Key Benefits
Reduces expression lines by helping to minimize the repetitive facial contractions that cause expression lines to form. In addition to relaxing expression lines, GABA also helps restore and maintain the skin barrier.
How It Works
Features the most advanced peptide technology that not only reduces the intensity of expression lines by inhibiting acetylcholine release from the nerve ending to the muscle, but also works at the epidermal level mitigating the release of acetylcholine from the keratinocyte which helps reduce its dissemination throughout the facial skin
Procedure Pairing Clinical Images
* Vehicle Control represents neuromodulator plus placebo serum
Stand-Alone Clinical Images
REFERENCES
1. Based on a Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Split-Face Study Evaluating Procedure pairing a Peptide Anti-Aging Serum with
OnabotulinumtoxinA in the treatment of Periorbital Facial Wrinkles. Results may vary.
2. Nguyen TQ, Zahr AS, Kononov T, Ablon G. A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum
Targeting Expression Lines. J Clin Aesthet Dermatol. 2021 May;14(5):14-21. Epub 2021 May 1. PMID: 34188744; PMCID: PMC8211334.
3. 3D PRIMOSCR Imaging (Canfield Scientific, Parsippany, NJ) clinical images were taken at the bilateral region of the face of both left and right side under standard light and
robust high pass filter. Based on results from a clinical study on 55 women, ages 35-60, after 12 weeks of twice-daily use. Data on file. Results may vary.
Updated Claim: 100% greater improvement in under-eye fine lines and wrinkles at rest
REFERENCES:
1. Based on a Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Split-Face Study Evaluating Procedure pairing a Peptide Anti-Aging Serum with
OnabotulinumtoxinA in the treatment of Periorbital Facial Wrinkles. Results may vary.
2. Nguyen TQ, Zahr AS, Kononov T, Ablon G. A Randomized, Double-blind, Placebo-controlled Clinical Study Investigating the Efficacy and Tolerability of a Peptide Serum
Targeting Expression Lines. J Clin Aesthet Dermatol. 2021 May;14(5):14-21. Epub 2021 May 1. PMID: 34188744; PMCID: PMC8211334.
3. 3D PRIMOSCR Imaging (Canfield Scientific, Parsippany, NJ) clinical images were taken at the bilateral region of the face of both left and right side under standard light and
robust high pass filter. Based on results from a clinical study on 55 women, ages 35-60, after 12 weeks of twice-daily use. Data on file. Results may vary.
4. Alisar S. Zahr, John Koch, Thu Q. Nguyen, Tatiana Kononov. A Novel Blend of Neuromodulating Peptides and Gamma Aminobutyric Acid to Regulate the Release of
Acetylcholine. Annual Meeting of the American Academy of Dermatology. VMX 2021. April 23-25, 2021
Formula Details
- Formulated for all skin types
- Formulated without parabens, phthalates, artificial dyes, alcohol and formaldehydes
- Fragrance-free
- Has a skin-neutral pH
Clinical Investigator Testimonials from Procedure-Pairing Study
“We’ve become so neuromodulator dominant that we think they can do everything, but the relaxation of the muscles can only do so much. Remember, people cannot see your neuromodulator or your fillers. What people see is the quality of your skin. Revox™ Line Relaxer not only enhances the results of neuromodulators, but it also rejuvenates the health of the skin over time which neuromodulators cannot do.”
-Dr. Shino Bay Aguilera
Board certified with a Fellowship in Dermatology from the American College of Osteopathic Dermatology, over 20 years in advanced training in lasers and aesthetics and a published author, clinical researcher, international Key Opinion Leader, and trainer. NOVA University, Assistant Professor of Dermatology and four other universities.
“For many patients, neuromodulator injections alone will not get them to a full result. During this double-blinded study, I clearly saw that one side was showing better results, and at the end of the study I learned that this was the side that paired the neuromodulator with Revox™ Line Relaxer. This product delivered results beyond what I thought a skin care product could do.”
-Dr. Justin Harper
Aesthetic Physician and healthcare innovator with a diverse background encompassing plastic surgery, dermatology, and medical technology
“What pleased me most about this study, was the significant improvement in wrinkles and fine lines in only 12 weeks compared to placebo. Especially in areas such as the under-eye area where patients were applying the study product but were not getting neuromodulator. I think every patient should be using this product. This product is another game changer from Revision Skincare.”
-Kimberly Schulz, MD, FAAD
Board Certified Dermatologist
Clinical Investigator Testimonial from Stand-Alone Study
“It is always exciting being on the forefront in research of new topical facial rejuvenating products and serums. The study we completed on Revox™ Line Relaxer provided statistically significant results in the softening of expression lines, wrinkles, and overall skin health. Patients on the active serum felt their skin looked more vibrant, less wrinkled, and results were seen as immediately as 15 minutes after application.”
-Glynis Ablon, MD, FAAD
Associate Clinical Professor UCLA
